184 related articles for article (PubMed ID: 35879821)
1. Physical activity behaviors in cancer survivors treated with neurotoxic chemotherapy.
Mizrahi D; Goldstein D; Trinh T; Li T; Timmins HC; Harrison M; Marx GM; Hovey EJ; Lewis CR; Friedlander M; Park SB
Asia Pac J Clin Oncol; 2023 Feb; 19(1):243-249. PubMed ID: 35879821
[TBL] [Abstract][Full Text] [Related]
2. Upper-limb dysfunction in cancer survivors with chemotherapy-induced peripheral neurotoxicity.
Mahfouz FM; Li T; Joda M; Harrison M; Kumar S; Horvath LG; Grimison P; King T; Goldstein D; Park SB
J Neurol Sci; 2024 Feb; 457():122862. PubMed ID: 38185015
[TBL] [Abstract][Full Text] [Related]
3. Health-Related Quality of Life in Cancer Survivors with Chemotherapy-Induced Peripheral Neuropathy: A Randomized Clinical Trial.
Bao T; Baser R; Chen C; Weitzman M; Zhang YL; Seluzicki C; Li QS; Piulson L; Zhi WI
Oncologist; 2021 Nov; 26(11):e2070-e2078. PubMed ID: 34390283
[TBL] [Abstract][Full Text] [Related]
4. Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes.
Li T; Timmins HC; Trinh T; Mizrahi D; Harrison M; Horvath LG; Grimison P; Friedlander M; Kiernan MC; King MT; Rutherford C; Goldstein D; Park SB
J Natl Compr Canc Netw; 2023 Feb; 21(2):125-132.e3. PubMed ID: 36791763
[TBL] [Abstract][Full Text] [Related]
5. Mobility in survivors with chemotherapy-induced peripheral neuropathy and utility of the 6-min walk test.
McCrary JM; Goldstein D; Wyld D; Henderson R; Lewis CR; Park SB
J Cancer Surviv; 2019 Aug; 13(4):495-502. PubMed ID: 31172429
[TBL] [Abstract][Full Text] [Related]
6. Evidence of slow and variable choice-stepping reaction time in cancer survivors with chemotherapy-induced peripheral neuropathy.
Menant JC; Goldstein D; Au K; Trinh T; van Schooten KS; McCrary JM; Harris CA; Forster BC; Park SB
Gait Posture; 2021 Sep; 89():178-185. PubMed ID: 34320441
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy-Induced Peripheral Neurotoxicity in Cancer Survivors: Predictors of Long-Term Patient Outcomes.
Battaglini E; Goldstein D; Grimison P; McCullough S; Mendoza-Jones P; Park SB
J Natl Compr Canc Netw; 2021 Jul; 19(7):821-828. PubMed ID: 34340206
[TBL] [Abstract][Full Text] [Related]
8. Assessing gait, balance, and muscle strength among breast cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): study protocol for a randomized controlled clinical trial.
Teran-Wodzinski P; Haladay D; Vu T; Ji M; Coury J; Adams A; Schwab L; Visovsky C
Trials; 2022 Apr; 23(1):363. PubMed ID: 35477489
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of behavioural and exercise interventions for the prevention and management of chemotherapy-induced peripheral neuropathy symptoms.
Tanay MAL; Armes J; Moss-Morris R; Rafferty AM; Robert G
J Cancer Surviv; 2023 Feb; 17(1):254-277. PubMed ID: 33710510
[TBL] [Abstract][Full Text] [Related]
10. Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.
Mizrahi D; Park SB; Li T; Timmins HC; Trinh T; Au K; Battaglini E; Wyld D; Henderson RD; Grimison P; Ke H; Geelan-Small P; Marker J; Wall B; Goldstein D
JAMA Netw Open; 2021 Feb; 4(2):e2036695. PubMed ID: 33587134
[TBL] [Abstract][Full Text] [Related]
11. Identifying trajectories and predictors of chemotherapy-induced peripheral neuropathy symptoms, physical functioning, and falls across treatment and recovery in adults treated with neurotoxic chemotherapy: the PATTERN observational study protocol (NCT05790538).
Winters-Stone KM; Krasnow SM; Horak FB; Mancini M; Cameron MH; Dieckmann NF; Stoyles SA; Roeland EJ
BMC Cancer; 2023 Nov; 23(1):1087. PubMed ID: 37946117
[TBL] [Abstract][Full Text] [Related]
12. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy.
Molassiotis A; Cheng HL; Lopez V; Au JSK; Chan A; Bandla A; Leung KT; Li YC; Wong KH; Suen LKP; Chan CW; Yorke J; Farrell C; Sundar R
BMC Cancer; 2019 Feb; 19(1):132. PubMed ID: 30736741
[TBL] [Abstract][Full Text] [Related]
13. Balance Deficits and Functional Disability in Cancer Survivors Exposed to Neurotoxic Cancer Treatments.
McCrary JM; Goldstein D; Trinh T; Timmins HC; Li T; Menant J; Friedlander M; Lewis CR; Hertzberg M; O'Neill S; King T; Bosco A; Harrison M; Park SB
J Natl Compr Canc Netw; 2019 Aug; 17(8):949-955. PubMed ID: 31390588
[TBL] [Abstract][Full Text] [Related]
14. Individually tailored whole-body vibration training to reduce symptoms of chemotherapy-induced peripheral neuropathy: study protocol of a randomised controlled trial-VANISH.
Streckmann F; Hess V; Bloch W; Décard BF; Ritzmann R; Lehmann HC; Balke M; Koliamitra C; Oschwald V; Elter T; Zahner L; Donath L; Roth R; Faude O
BMJ Open; 2019 Apr; 9(4):e024467. PubMed ID: 31023750
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-Induced Peripheral Neuropathy in Long-term Survivors of Childhood Cancer: Clinical, Neurophysiological, Functional, and Patient-Reported Outcomes.
Kandula T; Farrar MA; Cohn RJ; Mizrahi D; Carey K; Johnston K; Kiernan MC; Krishnan AV; Park SB
JAMA Neurol; 2018 Aug; 75(8):980-988. PubMed ID: 29799906
[TBL] [Abstract][Full Text] [Related]
16. Exercise-based rehabilitation for cancer survivors with chemotherapy-induced peripheral neuropathy.
McCrary JM; Goldstein D; Sandler CX; Barry BK; Marthick M; Timmins HC; Li T; Horvath L; Grimison P; Park SB
Support Care Cancer; 2019 Oct; 27(10):3849-3857. PubMed ID: 30756229
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).
Cheng HL; Molassiotis A
Asia Pac J Clin Oncol; 2019 Feb; 15(1):56-62. PubMed ID: 29873180
[TBL] [Abstract][Full Text] [Related]
18. Association of electrochemical skin conductance with neuropathy in chemotherapy-treated patients.
Mahfouz FM; Park SB; Li T; Timmins HC; Horvath LG; Harrison M; Grimison P; King T; Goldstein D; Mizrahi D
Clin Auton Res; 2022 Dec; 32(6):497-506. PubMed ID: 36129622
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy-induced peripheral neuropathy in the detroit research on cancer survivors (ROCS) cohort.
Sreeram K; Seaton R; Greenwald MK; Kamgar M; Assad H; Baird T; Schwartz AG; Ruterbusch J; Simon MS
Cancer Causes Control; 2023 May; 34(5):459-468. PubMed ID: 36934365
[TBL] [Abstract][Full Text] [Related]
20. Performance of the FACT-GOG-Ntx to assess chemotherapy-induced peripheral neuropathy (CIPN) in pediatric high risk Hodgkin lymphoma: report from the Children's Oncology Group AHOD 1331 study.
Parsons SK; Rodday AM; Pei Q; Keller FG; Wu Y; Henderson TO; Cella D; Kelly KM; Castellino SM
J Patient Rep Outcomes; 2023 Nov; 7(1):113. PubMed ID: 37947987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
